Filing Analysis
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding financial results.
ALX Oncology Holdings Inc. announced the resignation of Dr. Corey Goodman from his roles as Chairman and a member of the Board, effective June 29, 2026. The company has appointed independent director Scott Garland to succeed him as Chairman.
🚩 Red Flags
- Sudden departure of a Chairman/Board member, even if stated as 'personal reasons', can sometimes signal internal shifts or upcoming strategic changes in micro-cap biotech firms.
📋 Key Facts
- Dr. Corey Goodman resigned as Chairman and Board member on June 29, 2026, for personal reasons.
- The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Scott Garland has been appointed as the new Chairman of the Board, effective June 29, 2026.
- The Board restructured committee compositions: Rekha Hemrajani will chair the Audit Committee; Chris Takimoto will chair the Compensation Committee; and Daniel J. Curran will chair the Corporate Governance and Nominating Committee.
ALX Oncology Holdings Inc. entered into a $50 million secured multi-tranche term loan facility with HSBC Ventures USA Inc. to refinance existing debt and provide working capital.
🚩 Red Flags
- High interest rate floor (6.0% + Prime) in a floating environment.
- Security interests include 'substantially all' assets of the company/subsidiaries.
- Negative pledge on intellectual property, which is the primary value driver for a biotech firm.
📋 Key Facts
- Entered into a Loan Agreement on June 25, 2026, with HSBC Ventures USA Inc.
- Aggregate principal amount of up to $50,000,000 (including $10,000,000 uncommitted).
- $10,000,000 was borrowed at closing to refinance existing loans from Oxford Finance and Silicon Valley Bank.
- Additional $20,000,000 is available through June 30, 2028; another $10,000,000 is contingent on clinical milestones (Phase 2 ASPEN-09 study of Evorpacept and Phase 1 safety data for ALX2004).
- Term loans mature on June 1, 2030, with amortization starting July 1, 2028 or 2029 depending on an 'Interest Only Milestone Event'.
- Interest rate is floating: the greater of Prime Rate or 6.0%.
- Collateral includes substantially all assets of the Borrower and Guarantors, subject to a negative pledge on intellectual property.
ALX Oncology Holdings Inc. reported the results of its Annual Meeting of stockholders held on June 10, 2026. The meeting resulted in the election of Class II Directors, approval of executive compensation, and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of stockholders held on June 10, 2026.
- Election of Class II Directors: Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D. were elected to serve until 2029.
- Advisory vote on executive compensation was approved with 84,540,061 votes 'For' and 13,497,711 votes 'Against'.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 119,293,775 votes 'For'.
ALX Oncology Holdings Inc. announced its financial results for the first quarter ended March 31, 2026. The results were released via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 8, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial performance was included as Exhibit 99.1.
- The filing was signed by Harish Shantharam, Chief Financial Officer.
ALX Oncology Holdings Inc. has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings over 25 years of experience from companies including Crinetics Pharmaceuticals, Amgen, and Genentech, and will receive a base salary of $565,000 plus 800,000 stock options.
📋 Key Facts
- Jeff Knight appointed as Chief Development and Operating Officer effective April 13, 2026.
- Annual base salary set at $565,000 with a 40% target annual cash bonus.
- Granted a stock option to purchase 800,000 shares under the 2025 Inducement Equity Incentive Plan.
- Mr. Knight previously served as CDOO at Crinetics Pharmaceuticals and held leadership roles at Amgen and Genentech.
ALX Oncology Holdings Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished with the SEC filing.
📋 Key Facts
- Financial results for Q4 and full year 2025 announced on February 27, 2026
- Information furnished under Item 2.02 Results of Operations and Financial Condition
- Press release included as Exhibit 99.1
- Filing signed by CFO Harish Shantharam
ALX Oncology Holdings Inc. entered into an underwriting agreement to launch a significant public offering of common stock and pre-funded warrants, aiming to raise approximately $150 million in gross proceeds.
🚩 Red Flags
- Significant dilution: The issuance of over 76 million shares and nearly 18.5 million warrants represents a massive increase in share count.
- Low offering price: The $1.57/share pricing is relatively low, which often indicates a need for immediate liquidity to fund operations (common in biotech).
- Pre-funded warrants: Use of pre-funded warrants can be used by institutional investors to avoid exceeding ownership thresholds, but it also signals complex capital structure management.
📋 Key Facts
- Offering size: 76,979,112 shares of Common Stock at $1.57 per share.
- Pre-Funded Warrants: 18,574,120 warrants to purchase common stock at a price of $1.569 per warrant.
- Expected gross proceeds: Approximately $150 million (before expenses and excluding warrant exercise).
- Underwriters: Piper Sandler & Co., UBS Securities LLC, and Wells Fargo Securities, LLC.
- Closing date: Expected February 2, 2026.
- Warrant terms: Exercise price of $0.001 per share; includes beneficial ownership limitations (4.99% or 9.99%).
- Registration: Conducted via effective Form S-3 registration statement.
ALX Oncology reported positive exploratory clinical data for its CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA® for metastatic breast cancer. The company also disclosed preliminary cash and investment positions as of year-end 2025.
🚩 Red Flags
- Preliminary financial data is unaudited and subject to change upon completion of year-end closing procedures.
📋 Key Facts
- Released Phase 1b/2 clinical trial data for evorpacept + ZIIHERA® in heavily pretreated mBC patients.
- Topline findings indicate CD47 expression is predictive of evorpacept activity in HER2-positive mBC.
- Reported approximately $48.3 million in cash, cash equivalents, and investments as of December 31, 2025 (preliminary/unaudited).
- The company has not yet completed the year-end financial close process for FY2025.
ALX Oncology Holdings Inc. has amended its 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance. The amendment adds 1,300,000 shares, bringing the total pool under this specific plan to 2,800,000 shares.
🚩 Red Flags
- Potential dilution for existing shareholders due to the increased share reserve.
📋 Key Facts
- Effective date: January 21, 2026.
- Increased share reserve by 1,300,000 common shares.
- Total aggregate shares reserved under the Inducement Plan is now 2,800,000.
- The increase was adopted without stockholder approval per Nasdaq Listing Rules (inducement exception).
- Awards are restricted to new employees/directors as a material inducement to employment.
ALX Oncology Holdings Inc. filed an 8-K to furnish its quarterly earnings press release for the third quarter and full year ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of financial results (Item 2.02).
- Reporting period covers Q3 and Full Year ended September 30, 2025.
- The press release is furnished as Exhibit 99.1.
ALX Oncology announced a leadership transition involving the resignation of Chief Medical Officer Alan Sandler, M.D., and the appointment of Barbara Klencke, M.D., as interim consulting CMO. Additionally, Dr. Sandler will return to the Board of Directors while Dr. Klencke resigns from her Board seat.
🚩 Red Flags
- Resignation of Chief Medical Officer (key executive departure).
- Pausing of Research and Development Committee activities may indicate a shift in strategic focus or resource reallocation.
- Recent history of Nasdaq minimum bid price non-compliance (though currently compliant).
📋 Key Facts
- Alan Sandler, M.D. is resigning as Chief Medical Officer effective September 26, 2025.
- Barbara Klencke, M.D. will transition from the Board to a full-time consulting role as interim CMO effective September 17, 2025.
- Alan Sandler, M.D. is being re-appointed to the Board of Directors as a Class II director effective September 26, 2025.
- The Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement following a period from August 21 to September 4, 2025.
- The Board has paused activities of the Research and Development Committee.
ALX Oncology Holdings Inc. announced its second quarter and full year 2025 financial results and the appointment of Daniel Curran, M.D., to its Board of Directors. Dr. Curran joins as a Class III director and will serve on the Corporate Governance and Nominating Committee.
📋 Key Facts
- Appointment of Daniel Curran, M.D., as a Class III director effective August 12, 2025.
- Dr. Curran appointed to the Corporate Governance and Nominating Committee.
- Board size increased from six to seven directors.
- Dr. Curran will receive an initial award of 40,400 stock options vesting over 36 months.
- Company released Q2 and full year 2025 financial results via press release (Exhibit 99.1).
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 11, 2025. The meeting resulted in the election of two Class II directors and the approval of executive compensation and auditor ratification.
📋 Key Facts
- Annual Meeting held on June 11, 2025.
- Scott Garland was elected to serve as a Class II Director until the 2028 annual meeting (received 23,602,975 'For' votes).
- Dr. Barbara Klencke was elected to serve as a Class II Director until the 2028 annual meeting (received 30,835,565 'For' votes).
- Stockholders approved the advisory vote on compensation for Named Executive Officers (22,147,884 'For' votes).
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
- Signed by Harish Shantharam, Chief Financial Officer.
ALX Oncology Holdings Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The company has 180 days to regain compliance, potentially via a reverse stock split.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1))
- Potential for a reverse stock split to artificially inflate share price
- Risk of delisting if compliance is not met by October 20, 2025
📋 Key Facts
- Received written notice from Nasdaq Listing Qualifications Staff on April 23, 2025.
- Non-compliance is due to failure to meet the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) for 30 consecutive business days.
- The company has a compliance period of 180 calendar days, expiring October 20, 2025, to regain compliance.
- To regain compliance, the stock must close at $1.00 or higher for at least ten consecutive business days during the compliance period.
- A second 180-day period may be available if the company transfers to the Nasdaq Capital Market and meets other listing standards.
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 6, 2025
- Reporting period: Fourth quarter and full year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- The information under Item 2.02 is furnished rather than filed for purposes of Section 18.
ALX Oncology Holdings Inc. has announced a 30% workforce reduction to prioritize its pipeline and preserve cash. This restructuring includes the elimination of the President and Chief Scientific Officer position, effective April 2025.
🚩 Red Flags
- Significant workforce reduction (30%) indicating potential liquidity or strategic distress.
- Explicit mention of 'cash preservation strategy' as a driver for restructuring.
- Departure of a key executive (President and CSO) during a period of downsizing.
- Restructuring costs expected to impact Q1 2025 financial results.
📋 Key Facts
- Workforce reduction of approximately 30% of total employees.
- Estimated $2.2 million in severance and employee benefit expenses to be recognized in Q1 2025.
- Elimination of the President and Chief Scientific Officer position (Jaume Pons, Ph.D.).
- Reduction in force expected to be substantially completed by the end of May 2025.
- Dr. Pons will enter into a consulting agreement for up to one year following his separation.
ALX Oncology Holdings Inc. has appointed Harish Shantharam as Chief Financial Officer, effective January 21, 2025, replacing interim CFO Shelly Pinto. The company also expanded its Board of Directors with the appointment of two new independent directors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Harish Shantharam appointed CFO and Principal Financial Officer, effective Jan 21, 2025.
- Shelly Pinto transitions from Interim CFO to Senior VP, Finance and Chief Accounting Officer.
- Shantharam's compensation includes a $490,000 base salary and an option for 600,000 shares of common stock.
- Dr. Barbara Klencke appointed as Class II Director and member of Audit and R&D Committees.
- Dr. Chris Takimoto appointed as Class III Director and member of Compensation and R&D Committees.
- Board size increased to six directors.
ALX Oncology Holdings Inc. has adopted a 2025 Inducement Equity Incentive Plan to attract new talent. The plan reserves 1,500,000 shares of common stock for equity awards granted to new employees and directors.
📋 Key Facts
- Board adopted the 2025 Inducement Equity Incentive Plan effective January 16, 2025.
- Reserved 1,500,000 shares of common stock for issuance under this plan.
- Plan allows for nonstatutory stock options, SARs, restricted stock, RSUs, performance units, and performance shares.
- The plan was adopted without stockholder approval via the Nasdaq inducement award exception.
ALX Oncology experienced significant executive turnover, including the resignation of CFO Peter Garcia and the appointment of Dr. Alan Sandler as Chief Medical Officer. The filing also notes a reduction in Board size to four members.
🚩 Red Flags
- Departure of Chief Financial Officer (CFO)
- Simultaneous departure/resignation of a Board member and appointment of new CMO
- Reduction in Board size to four members
- Significant cash severance payout ($479,646) for the departing CFO
📋 Key Facts
- CFO Peter Garcia resigned effective November 8, 2024, for personal reasons.
- Dr. Alan Sandler appointed as Chief Medical Officer on November 10, 2024; he also resigned from the Board of Directors.
- Dr. Sandler's compensation includes a $575,000 annual base salary and a one-time $50,000 signing bonus.
- CFO Peter Garcia entered into a separation agreement including a $479,646 lump sum cash payment and 12 months of COBRA coverage.
- The Board of Directors was reduced to four members (three independent) as of November 10, 2024.
ALX Oncology Holdings Inc. announced the resignation of its Chief Financial Officer, Peter Garcia, effective November 8, 2024, citing personal reasons. The company has appointed Shelly Pinto, currently Senior VP of Finance and CAO, as Interim CFO.
🚩 Red Flags
- Sudden departure of a key executive (CFO) mid-quarter/post-earnings cycle.
📋 Key Facts
- CFO Peter Garcia resigned effective November 8, 2024, for personal reasons.
- The resignation is stated not to be due to any disagreement with the company's operations, policies, or practices.
- Shelly Pinto (SVP, Finance and CAO) appointed as Interim CFO and Principal Financial Officer.
- Company has commenced a search for a permanent replacement for the CFO role.
- The filing also includes the announcement of Q3 2024 financial results via press release.
ALX Oncology Holdings Inc. announced the resignation of its Chief Medical Officer, Sophia Randolph, M.D., Ph.D., effective October 11, 2024. The departure is reportedly not due to any disagreement with company operations or policies.
🚩 Red Flags
- Departure of a key C-suite executive (Chief Medical Officer) in a biotech company can impact clinical development timelines or investor confidence.
- Significant cash outflow via separation agreement ($503,880 plus COBRA and accelerated equity).
📋 Key Facts
- Sophia Randolph, M.D., Ph.D., resigned as Chief Medical Officer on September 30, 2024.
- Effective resignation date: October 11, 2024.
- Separation package includes a $503,880 lump sum cash payment and up to 18 months of COBRA coverage.
- Acceleration of vesting for outstanding stock options and RSUs for the 12-month period following separation.
- Dr. Randolph will enter into a consulting agreement to provide transition services on an hourly basis for up to 18 months.
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Signed by Peter Garcia, Chief Financial Officer.
ALX Oncology Holdings Inc. announced the appointment of Dr. Alan Sandler to its Board and committees, while simultaneously announcing the resignations of two directors who will transition to full-time executive roles within the company. These changes also resolve a previous Nasdaq non-compliance issue regarding director independence.
🚩 Red Flags
- None identified. The resignations were specifically noted as not being due to disagreements with the Board or Company.
📋 Key Facts
- Dr. Alan Sandler appointed as Class III Director, Audit Committee member, and Compensation Committee member effective August 5, 2024.
- Dr. Sandler granted 40,400 stock options vesting monthly over 36 months.
- Jaume Pons, Ph.D. and Sophia Randolph, M.D., Ph.D. resigned from the Board to focus on their roles as President/CSO and CMO, respectively.
- Board size decreased to six directors; current composition is five directors (four of whom are independent).
- The changes resolve a Nasdaq non-compliance notice regarding Rule 5605(a)(2) concerning director independence.
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 12, 2024. The meeting resulted in the election of three Class I directors and the approval of executive compensation and the appointment of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 12, 2024.
- Three Class I Directors elected: Corey Goodman, Ph.D., Jason Lettmann, and Sophia Randolph, Ph.D.
- Stockholders approved the advisory vote on compensation for Named Executive Officers (NEOs).
- Stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on May 9, 2024.
📋 Key Facts
- Reported date: May 9, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
- Company is listed on Nasdaq Global Select Market under ticker ALXO.
ALX Oncology Holdings Inc. announced the immediate resignation of two board members, Jack Nielsen and Dr. Itziar Canamasas, due to health reasons and a new professional position respectively. This has resulted in the company losing its majority of independent directors on the Board.
🚩 Red Flags
- Loss of board independence: The company no longer maintains a majority of independent directors.
- Nasdaq compliance risk: The company has officially entered a 180-day cure period to avoid delisting due to non-compliance with Nasdaq Listing Rule 5605(b)(1).
- Sudden departure of two board members in close succession.
📋 Key Facts
- Jack Nielsen resigned from the Board and all committees effective April 28, 2024, for health reasons.
- Dr. Itziar Canamasas resigned from the Board and all committees effective April 30, 2024, to take a new professional position.
- Scott Garland was reclassified from Class III director to Class II director effective May 1, 2024.
- The Board currently consists of six directors, only three of whom are considered independent.
- The Company notified Nasdaq on May 2, 2024, that it is relying on a 180-day cure period to restore a majority of independent directors per Nasdaq Listing Rule 5605(b)(1)(A).
- New committee compositions were approved for the Audit, Compensation, and Corporate Governance and Nominating Committees.
ALX Oncology Holdings Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal notice that a press release containing these results was issued on March 7, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: March 7, 2024.
- The filing includes a press release as Exhibit 99.1 regarding financial results.